Neuroinflammation is increasingly recognized as a driving force in neurological disease. When the brain encounters injury, infection, or toxic stimuli, resident glial cells react by releasing signalling molecules called pro-inflammatory cytokines, along with reactive oxygen and nitrogen species that can damage proteins, lipids, and DNA. In the short term, this response is protective, helping to contain threats and coordinate repair. But when the inflammatory state becomes chronic, it contributes to the progression of conditions including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis. Astrocytes sit at the centre of this process: they can either amplify inflammation or help resolve it, depending on the context and duration of the insult. Finding molecules that tip astrocytes toward a calmer, more balanced state is therefore a major goal of neuroinflammation research.

Ellagic acid has attracted attention precisely because of its dual antioxidant and anti-inflammatory credentials. Chemically, the molecule pairs a hydrophilic face bearing four hydroxyl groups and two lactone groups with a lipophilic backbone of two biphenyl rings, a structure that allows it to neutralize a broad spectrum of reactive species, including hydroxyl radicals and peroxynitrite, and to chelate metal ions that would otherwise catalyze free-radical production. Previous work has shown the compound protecting astrocytes from cadmium-induced oxidative injury, reducing nitrite production in macrophages exposed to inflammatory triggers, and easing mitochondrial dysfunction in heart cells exposed to the antipsychotic drug clozapine. What remained less clear was how ellagic acid would perform in astrocytes specifically provoked by a bacterial inflammatory stimulus.

To find out, the team prepared primary astrocyte cultures from the cerebral cortices of newborn Wistar rats, growing the cells for twenty days until they matured, following an ethically approved protocol at the Federal University of Pelotas. The cultures were then pretreated with ellagic acid at three concentrations, 50, 100, and 200 micromolar, for 48 hours before being exposed to lipopolysaccharide, or LPS, a component of the outer membrane of Gram-negative bacteria and a standard laboratory tool for switching on inflammatory pathways. LPS works by engaging Toll-like receptor 4 on the astrocyte membrane, which triggers an intracellular cascade that ramps up the expression of inflammatory mediators such as interleukin 1-beta, interleukin 6, and tumour necrosis factor-alpha, while mitochondrial dysfunction floods the cell with additional reactive species.

The inflammatory insult did exactly what the researchers expected. LPS exposure significantly reduced astrocyte viability as measured by the MTT assay, which tracks mitochondrial metabolic activity, while paradoxically increasing cell proliferation as measured by the sulforhodamine B protein-staining assay, a combination the authors interpret as distinct metabolic and growth responses to the same stimulus. LPS also drove up levels of reactive oxygen species and nitrite, drained the cells’ pool of protective sulfhydryl groups, and suppressed the activities of three key antioxidant enzymes: superoxide dismutase, catalase, and glutathione S-transferase. In other words, the cells were simultaneously producing more damaging oxidants and losing the enzymatic defences that would normally clear them, a textbook picture of oxidative stress.

Ellagic acid treatment substantially reversed this damage. At 100 and 200 micromolar, the compound significantly attenuated the LPS-induced rise in reactive oxygen species and nitrite levels, restored sulfhydryl content, and boosted the activities of superoxide dismutase and catalase back toward healthy levels; glutathione S-transferase activity was rescued even at the lowest dose tested. The compound also preserved cell viability at all three concentrations and curbed the abnormal proliferation at the highest dose. The authors suggest that the effect likely reflects both direct radical scavenging by the polyphenol’s chemical structure and a strengthening of the cells’ endogenous antioxidant machinery, possibly through the Nrf2 signalling pathway, a master regulator of antioxidant enzyme expression that ellagic acid has been shown to activate in other systems.

The anti-inflammatory results were more nuanced, and arguably more interesting. On the gene-expression front, LPS drove up messenger RNA levels for tumour necrosis factor-alpha, interleukin 1-beta, interleukin 6, and glycogen synthase kinase-3 beta, a multifunctional kinase with known roles in inflammatory regulation. Ellagic acid pretreatment at 100 micromolar prevented the increases in tumour necrosis factor-alpha and interleukin 1-beta, consistent with prior evidence that the compound can dampen the NF-kappa-B pathway, the transcriptional hub through which LPS switches on inflammatory genes. At the protein level, the picture diverged: LPS raised extracellular interleukin 6, but ellagic acid did not significantly change it, even though the compound had raised interleukin 6 mRNA. The authors caution that transcription and secretion follow different timelines and regulatory steps, so a single time point cannot capture the full story. Notably, LPS also suppressed interleukin 10, an anti-inflammatory cytokine, and ellagic acid at 100 micromolar fully prevented that reduction, a result that points toward selective rebalancing rather than blanket immune suppression.

The glycogen synthase kinase-3 beta finding demands particular care in interpretation. Ellagic acid increased the mRNA for this kinase in LPS-exposed astrocytes, and earlier work by Beurel and Jope showed that glycogen synthase kinase-3 beta activity can positively regulate interleukin 6 production in glial cells, which might suggest a pro-inflammatory consequence. But the Brazilian team is explicit that this kinase is controlled mainly by post-translational modification, especially its phosphorylation state, not by how much of it is transcribed. Elevated mRNA does not necessarily mean elevated enzymatic activity, and the study did not measure protein levels or phosphorylation. The same honesty applies to the signalling pathways themselves: neither NF-kappa-B activation nor Nrf2 expression was directly assessed in these experiments, so both remain plausible but unproven mechanisms for the effects observed.

The authors also lay out the study’s structural limitations with unusual thoroughness. The cultures were prepared by a standardized protocol but were not purified or checked immunocytochemically, so other glial cell types may have been present and contributing to the measurements. There were no ellagic-acid-only groups, which makes it harder to separate the compound’s intrinsic effects from its modulation of the LPS response, particularly for the interleukin 6 and glycogen synthase kinase-3 beta mRNA results. All analyses were performed at a single early time point, three hours after LPS exposure, and the key cytokines were examined only at the transcriptional level. And perhaps most importantly for anyone hoping to translate the findings, the concentrations used in the dish may not correspond to levels achievable in the human body, because ellagic acid has limited bioavailability and complex pharmacokinetics.

Those caveats notwithstanding, the overall picture is coherent and encouraging for a specific, testable idea: that a common dietary polyphenol can help inflamed astrocytes hold the line. In the study’s summary model, ellagic acid preserved cell viability, rebuilt antioxidant defences, trimmed the expression of two major pro-inflammatory cytokines, restored the anti-inflammatory cytokine interleukin 10, and pushed the astrocytic response toward what the authors describe as a more balanced and controlled state rather than a generalized shutdown of inflammatory signalling. The team frames the work as a foundation rather than a finish line, calling for time-course experiments, protein and phosphorylation measurements, direct assessment of the NF-kappa-B, Nrf2, MAPK, and glycogen synthase kinase-3 beta pathways, and eventually more complex models of neuroinflammation that capture the cellular richness of a living brain. For now, the humble pomegranate has once again supplied a molecule worth watching.

Subject of Research: Effects of the dietary polyphenol ellagic acid on oxidative stress and inflammatory responses in lipopolysaccharide-stimulated primary astrocyte cultures

Article Title: Ellagic acid regulates astrocytic responses under inflammatory conditions in primary astrocyte cultures: effects on oxidative stress, inflammatory cytokines, and glycogen synthase kinase-3β

Article References: da Rosa, T. M., da Silveira, L. M., Bona, N. P., Saraiva, J. T., da Silva, J. A., Domingues, W. B., de Souza, L. P., Nascimento, M. C., Campos, V. F., Stefanello, F. M., de Andrade, C. M., Pedra, N. S., & Spanevello, R. M. (2026). Ellagic acid regulates astrocytic responses under inflammatory conditions in primary astrocyte cultures: effects on oxidative stress, inflammatory cytokines, and glycogen synthase kinase-3β. Molecular Biology Reports, 53(1), Article 1534. https://doi.org/10.1007/s11033-026-12671-4

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12671-4

Keywords: ellagic acid, astrocytes, neuroinflammation, lipopolysaccharide, oxidative stress, inflammatory cytokines, GSK3-beta, antioxidant enzymes, NF-kappa-B, Nrf2 pathway, primary cell culture, Molecular Biology Reports